Karyopharm Therapeutics - KPTI Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KPTI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KPTI, but not buy additional shares or sell existing shares.
View KPTI analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued twelve-month price objectives for Karyopharm Therapeutics' shares. Their KPTI share price forecasts range from $6.00 to $18.00. On average, they expect the company's stock price to reach $9.88 in the next year. This suggests a possible upside of 66.5% from the stock's current price.
View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts.

Karyopharm Therapeutics' stock was trading at $6.43 at the start of the year. Since then, KPTI stock has decreased by 7.8% and is now trading at $5.93.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our KPTI earnings forecast.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its quarterly earnings results on Thursday, August, 4th. The company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.01. The company had revenue of $39.68 million for the quarter, compared to the consensus estimate of $36.38 million.

Karyopharm Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $155.00 million-$165.00 million, compared to the consensus revenue estimate of $160.03 million.

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KPTI stock can currently be purchased for approximately $5.93.

Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $473.26 million and generates $209.82 million in revenue each year. The company earns $-124,090,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

The company employs 442 workers across the globe.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com.